单倍体相合供者与脐带血异基因造血细胞移植后的免疫重建
Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation.
作者信息
Elmariah Hany, Brunstein Claudio G, Bejanyan Nelli
机构信息
Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 33612, USA.
Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
出版信息
Life (Basel). 2021 Jan 29;11(2):102. doi: 10.3390/life11020102.
Abstract
Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for a variety of hematologic diseases. However, this therapeutic platform is limited by an initial period when patients are profoundly immunocompromised. There is gradual immune recovery over time, that varies by transplant platform. Here, we review immune reconstitution after allogeneic HCT with a specific focus on two alternative donor platforms that have dramatically improved access to allogeneic HCT for patients who lack an HLA-matched related or unrelated donor: haploidentical and umbilical cord blood HCT. Despite challenges, interventions are available to mitigate the risks during the immunocompromised period including antimicrobial prophylaxis, modified immune suppression strategies, graft manipulation, and emerging adoptive cell therapies. Such interventions can improve the potential for long-term overall survival after allogeneic HCT.
摘要
异基因造血细胞移植（HCT）是多种血液系统疾病唯一具有潜在治愈可能的疗法。然而，这一治疗平台受到患者处于严重免疫功能低下的初始阶段的限制。随着时间推移，免疫功能会逐渐恢复，且因移植平台而异。在此，我们回顾异基因HCT后的免疫重建，特别关注两种替代供体平台，它们显著改善了缺乏HLA匹配的相关或无关供体的患者接受异基因HCT的机会：单倍体相合和脐带血HCT。尽管存在挑战，但仍有干预措施可降低免疫功能低下期间的风险，包括抗菌预防、改良免疫抑制策略、移植物操作以及新兴的过继性细胞疗法。此类干预措施可提高异基因HCT后长期总体生存的可能性。
相似文献
1
Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation.单倍体相合供者与脐带血异基因造血细胞移植后的免疫重建
Life (Basel). 2021 Jan 29;11(2):102. doi: 10.3390/life11020102.
2
Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.真实世界数据显示异基因造血细胞移植中种族和民族的趋势和结果：来自国际血液和骨髓移植研究中心的报告。
Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10. doi: 10.1016/j.jtct.2023.03.007. Epub 2023 Mar 15.
3
T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy.T细胞去除的单倍体相合造血细胞移植治疗儿童恶性肿瘤
Front Pediatr. 2022 Oct 14;10:987220. doi: 10.3389/fped.2022.987220. eCollection 2022.
4
Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.血液恶性肿瘤患者脐带血移植与匹配相关或匹配无关供者移植后 1 年生存率的降低。
Transplant Cell Ther. 2021 Aug;27(8):669.e1-669.e8. doi: 10.1016/j.jtct.2021.05.002. Epub 2021 May 12.
5
Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant.最优供者选择：不合型无关供者、脐带血或单倍体相合移植。
Blood. 2012 Mar 1;119(9):1972-80. doi: 10.1182/blood-2011-11-354563. Epub 2011 Dec 30.
6
Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.单份脐带血移植与未经处理的单倍体相合移植治疗完全缓解的成人急性髓系白血病。
Transplant Cell Ther. 2021 Apr;27(4):334.e1-334.e11. doi: 10.1016/j.jtct.2021.01.023. Epub 2021 Jan 28.
7
T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.移植后使用环磷酰胺的T细胞充足的单倍体相合供体移植：为缺乏HLA相合同胞供体的患者提供的一种新兴的标准治疗选择。
Bone Marrow Transplant. 2014 Aug;49(8):999-1008. doi: 10.1038/bmt.2014.62. Epub 2014 May 19.
8
Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients.同种异体半相合移植后环磷酰胺在儿科患者中的抗白血病作用有限。
Transplant Cell Ther. 2022 May;28(5):262.e1-262.e10. doi: 10.1016/j.jtct.2022.02.007. Epub 2022 Feb 11.
9
Overview of the progress on haploidentical hematopoietic transplantation.单倍体相合造血移植的进展概述
World J Transplant. 2016 Dec 24;6(4):665-674. doi: 10.5500/wjt.v6.i4.665.
10
Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.非洲裔美国血液系统恶性肿瘤患者的最佳供者：HLA单倍型相合亲属或脐带血移植
Biol Blood Marrow Transplant. 2020 Oct;26(10):1930-1936. doi: 10.1016/j.bbmt.2020.06.029. Epub 2020 Jul 7.
引用本文的文献
1
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.来特莫韦可降低接受移植后环磷酰胺治疗的 HLA 匹配和不匹配的异基因造血细胞移植患者的巨细胞病毒感染率。
Bone Marrow Transplant. 2025 Jul 5. doi: 10.1038/s41409-025-02670-7.
2
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.在成年人血液恶性肿瘤患者中，使用抗胸腺球蛋白和清髓性预处理进行单份脐带血移植后的免疫重建。
Ann Hematol. 2024 Jul;103(7):2475-2484. doi: 10.1007/s00277-024-05758-0. Epub 2024 Apr 18.
3
Differential analysis of immune reconstitution after allogeneic hematopoietic stem cell transplantation in children with Wiskott-Aldrich syndrome and chronic granulomatous disease.Wiskott-Aldrich 综合征和慢性肉芽肿病患儿异基因造血干细胞移植后免疫重建的差异分析。
Front Immunol. 2023 Jun 14;14:1202772. doi: 10.3389/fimmu.2023.1202772. eCollection 2023.
4
Immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide.异基因造血干细胞移植联合移植后环磷酰胺后的免疫重建情况
Stem Cell Investig. 2023 Apr 10;10:8. doi: 10.21037/sci-2023-002. eCollection 2023.
5
Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment.巴利昔单抗治疗后从类固醇难治性急性移植物抗宿主病中康复的患者的免疫重建
Front Oncol. 2022 Jul 15;12:916442. doi: 10.3389/fonc.2022.916442. eCollection 2022.
6
Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study.与造血干细胞再移植相关因素的分析：一项病例对照研究。
Rev Lat Am Enfermagem. 2022;30:e3569. doi: 10.1590/1518-8345.5794.3569.
本文引用的文献
1
Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation.与匹配的同胞供体异基因移植相比，脐血移植后巨细胞病毒特异性免疫恢复更慢。
Transplant Cell Ther. 2021 Feb;27(2):187.e1-187.e4. doi: 10.1016/j.jtct.2020.11.014. Epub 2020 Dec 21.
2
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.双份无关脐血与 HLA 单倍体相合骨髓移植：BMT CTN 1101 试验。
Blood. 2021 Jan 21;137(3):420-428. doi: 10.1182/blood.2020007535.
3
Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity.选择异基因造血细胞移植供者以优化自然杀伤细胞的同种异体反应性。
Semin Hematol. 2020 Oct;57(4):167-174. doi: 10.1053/j.seminhematol.2020.10.005. Epub 2020 Nov 7.
4
Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.来特莫韦用于预防单倍体相合及配型不合的成年供者异基因造血细胞移植中巨细胞病毒再激活，移植后使用环磷酰胺预防移植物抗宿主病。
Transplant Cell Ther. 2021 Jan;27(1):85.e1-85.e6. doi: 10.1016/j.bbmt.2020.10.009. Epub 2020 Oct 11.
5
Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.人疱疹病毒6的预防性膦甲酸钠：对减低剂量预处理脐带血移植后造血植入的影响。
Transplant Cell Ther. 2021 Jan;27(1):84.e1-84.e5. doi: 10.1016/j.bbmt.2020.10.008. Epub 2020 Oct 11.
6
Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.KIR 和 NK 细胞重建对造血干细胞移植结局的影响。
Front Immunol. 2020 Sep 2;11:2022. doi: 10.3389/fimmu.2020.02022. eCollection 2020.
7
Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation.基于阿仑单抗的 T 细胞耗竭对异基因造血干细胞移植后体外移植物组成变化和早期免疫重建的影响。
Cytotherapy. 2021 Jan;23(1):46-56. doi: 10.1016/j.jcyt.2020.08.003. Epub 2020 Sep 15.
8
Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide.非清髓性、相关 HLA 单倍体相合或无关供体外周血移植和移植后环磷酰胺后缩短疗程免疫抑制治疗。
Biol Blood Marrow Transplant. 2020 Nov;26(11):2075-2081. doi: 10.1016/j.bbmt.2020.07.037. Epub 2020 Aug 18.
9
Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.经典型霍奇金淋巴瘤免疫检查点抑制后采用移植后环磷酰胺的非清髓性异基因移植：一项回顾性队列研究
Biol Blood Marrow Transplant. 2020 Sep;26(9):1679-1688. doi: 10.1016/j.bbmt.2020.06.012. Epub 2020 Jun 24.
10
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.一项多中心 1 期研究，评估纳武利尤单抗用于异基因移植后复发血液系统恶性肿瘤。
Blood. 2020 Jun 11;135(24):2182-2191. doi: 10.1182/blood.2019004710.
Zotero 插件